Alto Neuroscience (ANRO) Net Cash Flow (2023 - 2026)

Alto Neuroscience has reported Net Cash Flow for 4 years, with the latest figure at $87.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 1271.26% year-over-year to $87.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.0 million (up 330.95% YoY) and the FY2025 annual result came in at $8.3 million, down 90.39% from the prior year.
• Net Cash Flow improved to $87.3 million in Q1 2026 per ANRO's latest filing, from $38.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $123.4 million in Q1 2024 and troughed at -$13.5 million in Q4 2024.
• A 4-year average of $16.6 million and a median of -$7.5 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow tumbled 143.12% in 2024, then soared 1271.26% in 2026.
• Over 4 years, Net Cash Flow stood at $31.3 million in 2023, then sank by 143.12% to -$13.5 million in 2024, then jumped by 386.9% to $38.7 million in 2025, then jumped by 125.75% to $87.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $87.3 million, $38.7 million, and -$9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.